The Rx EnLyte (ENL) EnBrace HR Story

"Science has discovered and documented that a big part of the root cause of mental disease lies within brain biochemistry dysfunction and genetic vulnerability. The good news is that effective and safe Rx therapies to restore and normalize brain chemistry and nullify genetic polymorphisms are available for prescription use now to use as monotherapy or adjunctively. Complete folate therapies EnLyte and EnBrace HR can help normalize brain chemistry which equates to clinical improvement based on well-designed studies. These topics are addressed simply in the presentation The Use of Folates in Depression, "The Rx EnLyte/EnBrace HR Story". Please learn more about these tools to enhance your treatment options for depression"

Towny Robinson
Inventor Enlyte/EnBraceHR
CEO, JayMac Pharmaceuticals



Use of Folates in Depression "The Rx EnLyte (ENL)/EnBrace HR Story"

Presented By:

Towny Robinson, B.S., M.S.

CEO, JayMac Pharmaceuticals • Inventor EnLyte/EnBrace HR (337) 351-6721

Diane Pratt

VP Sales • Folate Therapy Expert

(985) 629-5825

TOWNY ROBINSON



Experience:

- 30 years Schering Plough Sales, Marketing, Development
- •15 years JayMac Pharmaceuticals, CEO

Expertise:

- Folate Therapy
- Methylation Biochemistry
- Epigenetics/Genetics/MTHFR SNP
- Pharmaceutical Industry

JEFFREY COLLINS



Folate Therapy Expert In Training

DIANE PRATT



Experience:

• 30 Years - Sales & Development

Expertise:

- Folate Therapy
- Patient Educator
- Pharmaceutical Industry

DIATHESIS (ROOT CAUSE) THEORY OF DEPRESSION

CNS BIOCHEMICAL DYSFUNCTION



UNTOWARD STRESS FACTORS



CLINICAL PSYCHIATRIC RISK

- LOW

 NEUROTRANSMITTER

 PRODUCTION &

 BALANCE
- · LOW SAM-e
- LOW GLUTATHIONE
- HIGH HOMOCYSTEINE

ENLYTE /
ENBRACE HR
NORMALIZE AND
BALANCE CNS
BIOCHEMISTRY

- CHILDHOOD ABUSE (ALL FORMS)
- EXTREME LOSS
- MAJOR FEARFUL EVENTS
- ADDICTION
- DISEASE
- TOXIC EXPOSURE
- POVERTY
- POOR NUTRITION

- MAJOR DEPRESSIVE DISORDER
- ANXIETY DISORDER
- BIPOLAR DEPRESSION
- SCHIZOPHRENIA
- · ADHD
- ADDICTION

Journal of Psychiatric Research July 2017

The Association of Folate and Depression: A Meta-Analysis of 3470 International Studies and Over 500,000 Patients

RESULTS: All populations (geriatric, adult, perinatal, child/adolescent) had significantly lower levels of folate than their non-depressed counterparts.

CONCLUSION: Individuals with depression have lower serum levels of folate and dietary folate intake than individuals without depression.



CONTRIBUTORS TO FOLATE DEFICIENCY

GENETICS	ETHNIC RISK		CONDITIONS	DRUGS
MTHFR and other B Vitamin Polymorphisms	 Hispanic Mediterranean Chinese African-American 	•	Pregnancy Breast Feeding Kidney Disease Liver Disease Cancer Canker Sores	Lamictal Metformin Methotrexate Corticosteroids NSAIDs Antibiotics Anticonvulsants Oral Contraceptives Cholesterol Lowering Diuretics H2 Antagonists

Poor Nutrition

• Statins

WHAT IS MTHFR POLYMORPHISM?

 A Minor Genetic Defect That Prevents Normal Production of the Enzyme
 Methylenetetrahydrofolate Reductase. This Defect Reduces Methylfolate Production, Leading to Low Neurotransmitter Production and an Increased Risk For Psychiatric Disorders

COMMON MTHFR SNPS

C677T - Heterozygous - 40% Reduction

C677T - Homozygous - 70% Reduction

A1298C - Heterozygous - 30% Reduction


A1298C - Homozygous - 50% Reduction

40 KNOWN STRAINS

Treatment resistant depression has a 76% likelihood of being positive for the MTHFR polymorphism and suspected etiology in TRD.

Duprey: Neuropsychiatry, Volume 6, Issue 2, 2016

SIMPLIFIED METHYLATION BIOCHEMISTRY



Stephen Stahl, MD Stephen Stahl's Folate Recommendations

- Suboptimal Folate Levels in Depressed Patients (Adjunct to Antidepressant)
- Hyperhomocysteinemia in Schizophrenia Patients (Adjunct to Antipsychotic)
- Enhancement of Antidepressant Response at the Initiation of Treatment
- Cognitive or Mood Symptoms in Patients with MTHFR
 (Methylenetetrahydrofolate Reductase) Deficiency/ MTHFR Polymorphism
- In Pregnancy for Normal Epigenetic Expression

Folate in Depression:

Efficacy, Safety, Differences in Formulations and Clinical Issues

Maurizio Fava, MD
Chief of Psychiatry, Harvard, MGH

Journal of Clinical Psychiatry 2009:

- "Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder..."
- "Consider folate supplementation from the start of treatment in patients with depression and low or normal folate levels"
 - "Folate appears to be well tolerated"

American Psychiatric Association Recommendations

APA MDD Guidelines for Treatment 2010

"Considering the modest evidence that supports folate as an augmentation strategy and its attractive risk-benefit profile, folate can be recommended as reasonable adjunctive strategy for MDD that carries little risk."

APA CAM MDD Guidelines for Treatment 2009

"Studies to date demonstrate efficacy of augmentation of antidepressants with folic acid, folinic acid, and L-methylfolate for MDD. We advocate and recommend folate/methylfolate and omega-3's as effective strategies for MDD. Folate and methylfolate monotherapy may benefit certain depressed populations."





Can Keep Them "Happy For Life"

By Treating The Root Causes of Depression



(geriatric, adult, perinatal, child/adolescent)
had significantly lower levels of folate than their
non-depressed counterparts."

A. Bender et al The Association of Folate and Depression A Meta analysis, Journal of Psychiatric Research 2017, 3470 International Studies

TEAM METHYLATION

PRE-METABOLIZED COENZYMES AND COFACTORS, BRAIN READY INGREDIENTS

L-Methylfolate Magnesium	7mg
Folinic Acid	2.5mg
Dihydrofolate	1mg
B12 (Methylcobalamin)	25mcg
B12 (Adenosylcobalamin)	25mcg
B6 (Pyridoxal-5-Phosphate)	25mcg
B1 (Thiamine Pyrophosphate)	25mcg
B2 (Flavin Adenine Dinucleotide)	25mcg
B3 (Nicotinamide Adenine Dinucleotide)	25mcg
PS-Omega-3 (Phosphatidylserine, EPA,DHA)	23mg
Magnesium Ascorbate	24mg
Magnesium L-Threonate	1mg
Zinc Ascorbate	1mg
Betaine	500mcg
Citric Acid Monohydrate	1.83mg
Sodium Citrate	3.67mg
CoQ10	500mcg
Bioperine (B Vitamin Bioenhancer)	25mg

CNS Biochemical Actions


- 1. Normalizes and balances Neurotransmitter production (serotonin, dopamine, norephinephrine, epinephrine & GABA)
- 2. Normalizes production of endogenous SAM-E for methylation of DNA, RNA, proteins and lipids
- 3. Normalizes Glutathione production
- 4. Reduces high Homocysteine

"EnLyte/EnBrace HR combines all the coenzymes, cofactors, and omegas needed within the Methylation Cycles to treat the biochemical root cause of depression."

ANDREW FARAH, MD

Chief of Psychiatry, High Point Section of UNC Health Care & Clinical Study Investigator NOTE: Product Ingredients - Maroon

Methylation Chart



Oxidative stress

6. Impaired myelination

THE JOURNAL OF CLINICAL PSYCHIATRY


MAY 2016


Correlation of Clinical Response With Homocysteine Reduction During Therapy With EnLyte/EnBrace HR in Patients With MDD Who Are Positive for MTHFR C677T or A1298C Polymorphism

Andrew Farah. MD

ADULT PATIENT RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY


OBJECTIVE: This study was designed to evaluate the efficacy and safety of EnLyte/EnBrace HR as monotherapy in adults with major depressive disorder (MDD) who were also positive for at least 1 methylenetetrahydrofolate reductase (MTHFR) polymorphism associated with depression and further test the hypothesis that EnLyte/EnBrace HR will lower homocysteine in a majority of clinical responding patients.





NO SIDE EFFECT WAS REPORTED AT GREATER RATE THAN PLACEBO

ONSET OF ACTION 2 WEEKS





Prevention of Depression in Women Trying to Conceive and During Pregnancy Marlene P. Freeman, MD et al, Annals of Clinical Psychiatry February 2019



Results

Figure 1. Mood and Quality of Life Outcomes




Figure 1. The aim for Group 1 was to prevent depression relapse, and the aim for Group 2 was to improve depression symptoms, measured through several mood and quality of life questionnaires. Trends shown by group for the primary mood outcome measure, the MADRS (Montgomery-Asberg Depression Rating Scale) in dark blue; for secondary mood measures, the QIDS—SR (Quick Inventory of Depressive Symptomatology-Self Report) in orange and the EPDS (Edinburgh Postnatal Depression Scale) in light blue; and for a quality of life outcome, the QLESQ-SF (Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form) in green. Group 1 experienced no significant changes in any of the four measures, and Group 2 experienced significant improvements in the mood questionnaires but not the quality of life questionnaire. All ANOVAs indicating significance are reported in Table 3.

Conclusion:

• Study results suggest EnBrace HR is a novel and well tolerated intervention with efficacy for the prevention and treatment of depression among women planning pregnancy and who are pregnant.

HOW TO USE

EnLyte and EnBrace HR can be used as monotherapy or adjunctive therapy as determined by a licensed medical practitioner

ADJUNCTIVE THERAPY

- Combine with SSRIs or SNRIs from the start to enhance results, reduce dropout rates and for non-responsive patients
- Augmentation can precede atypical antipsychotic augmentation therapy

MONOTHERAPY

MTHER Positive

	111111111111111111111111111111111111111				
•	MTHFR Suspected E	ected Based on Family History of:			
	Mental Illness	Miscarriages or Birth Defects			
	Addiction	☐ Cardiovascular Issues			

- Diabetes
- Before, during and after pregnancy
- Addiction Support
- Adolescents to Prevent Suicidal or Violent Ideation
- Geriatrics

ENLYTE / ENBRACE HR HELPS WITH SYMPTOMS LIKE...

- Depressed Mood
- Apathy / Loss of Interest
- Problems Concentrating

- Insomnia
- Anxiety/Worry
- Irritability

- Inattention
- Hyperactivity / Impulsivity
- MTHFR Genetic Issues



PATIENTS CAN FEEL COMPLETELY SAFE

Possible Side Effects	EnLyte	SSRI's	SNRI's
Weight Gain	No!	Yes	Yes
Loss of Libido, difficulty achieving erections, inability to reach orgasm	No!	Yes	Yes
Increased thoughts of suicide, and aggression in adolescents & adults	No!	Yes	Yes
Drowsiness or Confusion	No!	Yes	Yes
Nervousness & Agitation	No!	Yes	Yes

Adapted from: Consumer Reports Best Buy Drugs. Using antidepressants to treat depression: comparing efficacy, safety, and price. 2012



GLUTEN FREE DYE FREE CALCIUM FREE CASEIN FREE

Rx Only Insurance, Medicaid, Medicare and Medicare Supplement Coverage







IDENTICAL INGREDIENTS + COVERAGE OPTIONS -

FILLING THE PRESCRIPTION

THE PROVIDER:

The Patient's Mail Order Prescription Plan May Be A Cost Effective Option. You will find our easy to use fax form on EnLyteRX.com or by calling 985.629.5825. Please fax the form to our Reimbursement Department who will help determine the most cost effective option for your patient.

THE PATIENT:

Someone from our Reimbursement Department will be reaching out to help you determine the most cost effective way to receive your prescription.

Our Friendly Customer Service Team Is Here To Help You Obtain Your EnLyte or EnBrace HR Prescription.

We Look Forward To Speaking With You!

985-629-5825

Now Offering A Special Introductory Price for New Patients! First 30-Day Supply of EnLyte (ENL) & EnBrace HR for Only \$29.95!

EnLyte (ENL) & EnBrace HR

CLICK THE "PRESCRIBE NOW" BUTTON FOR \$29.95 SPECIAL OFFER

Prescribe Now



Here is Our Simple Process:

STEP 1:

Follow the link above (bookmark in your favorite web browser), Fill out patient and provider information and click "submit"

OR

Fax us a patient fax form (Download It Here)

STEP 2:

A reimbursement specialist will contact your patient to help assist in finding the most cost-effective option to obtain EnLyte or EnBrace HR, whether through Insurance or our Cash Pay program.

STEP 3:

If the product is covered on the patient's insurance, we will contact your office with prescribing details. If the product is not covered on the patient's insurance, nothing else is needed from your office. Your patient will have access to the Manufacturer's Discount Option and pay no more than \$52 for their EnLyte or EnBrace HR!